Established in 1993 by Clal Industries and Investments Ltd. (CII), Clal Biotechnology Industries Ltd. (TASE: CBI) is a specialized investment company, the largest of its kind in Israel. Having Teva Pharmaceutical Industries (15%), the world's largest manufacturer of generic drugs, as a strategic partner, CBI is focused on identifying and building biotechnology companies with proprietary biopharmaceutical solutions to unmet clinical needs, clinical proof of concept and large potential markets

MediWound is an Israeli company which develops and commercializes Debrase Gel Dressing - an enzymatic debriding agent. Debrase swiftly and selectively removes the eschar layer from burn tissue. Pre-marketing stage for Company's products

D-Pharm is a biopharmaceutical company pioneering the development of lipid-based therapeutic strategies. The company designs and develops innovative drugs for the treatment of devastating brain disorders and has two Phase II products. DP-b99 completed successfully a phase IIb trial in early 2007, and recieved an approval from FDA to start with Phase III

CureTech is a biotechnology company focused on the research, development and commercialization of novel broad-spectrum immunotherapy products for the treatment and control of cancer

Andromeda Biotech is focused on development of innovative treatment for autoimmune diabetes.
The company lead product is DiaPep277, a novel therapeutic approach in treating type 1 diabetes (T1D), is currently in phase III clinical studies